| Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. | |
| | |
MedLine Citation:
|
PMID: 12653675 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of the present study was to compare the antihypertrophic effects of blockade of the renin-angiotensin system (RAS), vasopeptidase inhibition and calcium channel antagonism on cardiac and vascular hypertrophy in diabetic spontaneously hypertensive rats (SHR). SHR with streptozotocin-induced diabetes were treated with one of the following therapies for 32 weeks: the angiotensin-converting enzyme (ACE) inhibitor captopril (100 mg/kg); the angiotensin AT(1) receptor antagonist valsartan (30 mg/kg); a combination of captopril with valsartan; the vasopeptidase inhibitor mixanpril (100 mg/kg); or the calcium channel antagonist amlodipine (6 mg/kg). Systolic blood pressure and cardiac and mesenteric artery hypertrophy were assessed. Mean systolic blood pressure in diabetic SHR (200+/-5 mmHg) was reduced by captopril (162+/-5 mmHg), valsartan (173+/-5 mmHg), mixanpril (176+/-2 mmHg) and amlodipine (159+/-4 mmHg), and was further reduced by the combination of captopril with valsartan (131+/-5 mmHg). Captopril, valsartan and mixanpril reduced heart and left ventricle weights by approx. 10%. The combination of captopril and valsartan further reduced heart weight (-24%) and left ventricular weight (-29%). Amlodipine did not affect cardiac hypertrophy. Only mixanpril and the combination of captopril and valsartan significantly reduced mesenteric weight. The mesenteric wall/lumen ratio was reduced by all drugs, and to a greater extent by the combination of captopril and valsartan. We conclude that optimizing the blockade of vasoconstrictive pathways such as the RAS, particularly with the combination of ACE inhibition and AT(1) receptor antagonism, is associated with antitrophic effects in the context of diabetes and hypertension. In contrast, calcium channel blockade, despite similar effects on blood pressure, confers less antitrophic effects in the diabetic heart and blood vessels. |
| | |
Authors:
|
Markus Lassila; Belinda J Davis; Terri J Allen; Louise M Burrell; Mark E Cooper; Zemin Cao |
Related Documents
:
|
9797175 - Inhibition of tissue angiotensin converting enzyme activity prevents malignant hyperten... 9481735 - The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental c... 3064595 - Efficacy of captopril in hypertensive diabetic patients. 3279725 - Additive effects of moderate dietary salt reduction and captopril in hypertension. 10588685 - Residual delay maps unveil global patterns of atmospheric nonlinearity and produce impr... 1131165 - Hemodynamic syndromes in apex-cardiography. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical science (London, England : 1979) Volume: 104 ISSN: 0143-5221 ISO Abbreviation: Clin. Sci. Publication Date: 2003 Apr |
Date Detail:
|
Created Date: 2003-03-25 Completed Date: 2003-07-22 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7905731 Medline TA: Clin Sci (Lond) Country: England |
Other Details:
|
Languages: eng Pagination: 341-7 Citation Subset: IM |
Affiliation:
|
Baker Heart Research Institute, P.O. Box 6492, St Kilda Road Central, Melbourne, Victoria 8008, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alanine
/
analogs & derivatives*,
therapeutic use Amiodarone / therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Animals Calcium Channel Blockers / therapeutic use Captopril / therapeutic use Cardiomegaly / blood, etiology, prevention & control* Diabetes Mellitus, Experimental Drug Therapy, Combination Enzyme Inhibitors / therapeutic use Hypertension / blood, complications*, drug therapy Hypertrophy Male Mesenteric Arteries / pathology Neprilysin / antagonists & inhibitors Rats Rats, Inbred SHR Receptor, Angiotensin, Type 1 Receptors, Angiotensin / antagonists & inhibitors Renin / blood Renin-Angiotensin System / drug effects* Tetrazoles / therapeutic use Valine / analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Calcium Channel Blockers; 0/Enzyme Inhibitors; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Angiotensin; 0/Tetrazoles; 137862-53-4/valsartan; 156039-69-9/mixanpril; 1951-25-3/Amiodarone; 56-41-7/Alanine; 62571-86-2/Captopril; 7004-03-7/Valine; EC 3.4.23.15/Renin; EC 3.4.24.11/Neprilysin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Contrasting neurovascular findings in chronic orthostatic intolerance and neurocardiogenic syncope.
Next Document: High-dose heparin fails to improve acute lung injury following smoke inhalation in sheep.